Replimune Reports Fiscal Fourth Quarter and Year Ended 2023 Financial Results and Provides Corporate Update

18.05.2023 - Topline data disclosure from the registration-directed CERPASS clinical trial of RP1 combined with Libtayo (cemiplimab-rwlc) in cutaneous squamous cell carcinoma (CSCC) on track for Q3 2023 and Biologics License Application (BLA) submission on track ...

Related Keywords

United States ,American ,Arleen Goldenberg ,Bristol Myers Squibb ,Chris Brinzey ,Jean Franchi ,Philip Astley Sparke ,Andrew Schwendenman ,Program Highlights Milestones ,American Transplant Congress ,Exchange Commission ,Securities Exchange ,Nasdaq ,Corporate Communications ,Replimune Group Inc ,Vice President ,Chief Accounting ,Securities Act ,Securities Exchange Act ,Annual Reports ,Quarterly Reports ,Consolidated Statements ,Ended March ,Balance Sheet Data ,Replimune Group ,